

Completed operational build

An ambition to transform the lives of millions

CREATING AND BUILDING COMPANIES FROM LEADING SCIENCE

Forcefield has developed a strategy focused on harnessing the potential of its first-in-class cardioprotective proteins to retain heart function following heart attacks, an area devoid of any significant advancements in the past two decades. Forcefield was founded by Syncona and Professor Mauro Giacca, a leading authority in cardiovascular disease, who is the Head of the School of Cardiovascular and Metabolic Medicine & Sciences at King's College London.

PLANNING A PATH TO THE CLINIC

The company has plans for its progression towards clinical development as it works towards the initiation of its planned Phase I/II trial. There is a significant commercial opportunity within the field, with heart attacks being the number one global cause of death. Syncona has worked closely with the Forcefield team on its financing and clinical strategy as it seeks to bring its therapies to patients in an area of high unmet need.

ESTABLISHING A LEADING MANAGEMENT TEAM

In line with Syncona's approach of establishing world-class management teams at our portfolio companies, in September 2023 Syncona Executive Partner John Tsai, MD was appointed as Chief Executive Officer of Forcefield. He was previously President, Global Drug Development and Chief Medical Officer at Novartis AG and has over 20 years of experience in bringing innovative therapies to market across geographies and therapeutic areas. John's proven track record in leading transformational organisational growth and strategy, along with expertise in regulatory approval, commercial launches, medical affairs, and great leadership skills make him ideally placed to lead Forcefield in progressing its cardioprotective protein technology towards clinical development.

£20.0m

Series A commitment



2024 PORTFOLIO HIGHLIGHT

Further commitment to a Series A financing

During the year Syncona committed to a Series A financing of Forcefield, following an initial seed investment in 2021. This funding will support Forcefield as it works towards the initiation of its Phase I/II trial. Post-period end Forcefield attracted a further £10.0 million Series A commitment from Roche Venture Fund, with Syncona's total commitment to the Series A being £20.0 million.





Forcefield has achieved a number of important milestones this year, including launching a Series A financing and completing the build out of its team. I am excited to lead this company on the next stage of its journey as it works towards the initiation of its Phase I/II clinical trial.”

John Tsai

FORCEFIELD CEO AND
SIML EXECUTIVE PARTNER

